Navigation Links
Etanercept shows promise for treating dermatomyositis
Date:6/16/2011

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, but larger studies are needed to further investigate the safety and efficacy of etanercept. Results of this clinical trial are available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.

Dermatomyositis is a type of inflammatory myopathy that causes inflammation and progressive weakness in muscles, and is often accompanied by a purple or red skin rash. In some patients the standard treatment for dermatomyositis is prednisone, but despite steroid therapy many patients continue to experience disabling weakness and have the added unpleasant side affects associated with the steroids. Prior studies suggest that tumor necrosis factor (TNF) may play a role in the development of dermatomyositis. TNFa type of protein molecule involved in systemic inflammationis associated with other inflammatory diseases including rheumatoid arthritis, ankylosing spondylitits, and psoriatic arthritis, all of which seem to be responsive to etanercept therapy in studies.

"Given the positive response of other inflammatory diseases to etanercept, our pilot study aimed to assess the safety and tolerability of this drug in dermatomyositis, along with the feasibility of a forced prednisone taper," said Anthony Amato, MD, with the Department of Neurology at Brigham and Women's Hospital and Harvard Medical School in Boston, Massachusetts. Researchers conducted a double-blind, placebo-controlled trial of etanercept (50 mg weekly) in16 patients with dermatomyositis. The year-long trial randomized 11 participants to etanercept and 5 to placebo, with subjects tapered off prednisone in a standardized schedule over the first 24 weeks of the study.

Trial results revealed no significant increase in adverse event rates in the treatment group compared to placebo. Of the 11 subjects treated with etanercept, 5 were successfully tapered from steroid therapy, with a median time to treatment failure (inability to wean off prednisone on schedule) in this group of 358 days. All placebo subjects were treatment failures with a median of 148 days to failure of treatment. Researchers reported that 5 etanercept-treated participants and 1 placebo-treated participant developed a worsening rash. After week 24 the median of the average prednisone dosage was 29.2 mg/day in the placebo group and 1.2 mg/day in the etanercept cohort.

Additionally, two etanercept-treated participants developed elevated anti-nuclear antibodies during the study, but none developed systemic lupus erythematosus. The authors noted that the small sample size and allowance of rescue treatment in this trial limit conclusions of etanercept efficacy to those related to steroid-sparing. "Etanercept was safe and well-tolerated in participants in our one-year study," concluded Dr. Amato. "Further study of the safety and efficacy of etanercept as a dermatomyositis treatment is warranted."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Heightened immunity to colds makes asthma flare-ups worse, U-M research shows
2. Ancestry plays vital role in nutrition and disease, study shows
3. New animal study shows promise for development of Parkinsons disease drug
4. Drug shows promise in prostate cancer spread to bone
5. PARTNER shows similar 1-year survival for catheter-based AVR and open AVR in high-risk patients
6. Combination antibody therapy shows promise in metastatic melanoma
7. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
8. Combination therapy shows promise for rare, deadly cancer caused by asbestos
9. Melanoma Vaccine Shows Promise in Trial
10. Violence Doesnt Make TV Shows More Enjoyable for Kids
11. U.S. Southeast Stroke Belt Also Shows Higher Rates of Cognitive Decline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Fresno, CA (PRWEB) , ... January 18, 2017 ... ... is pleased to announce that their Vice President of Franchise Development, Paula Turner ... , This award-winning business program, which features the insights of top business leaders ...
(Date:1/18/2017)... ... ... At Hallmark Nameplate, their commitment to quality is what sets them apart. The ... certification is another way they are making constant strides to provide all customers with ... The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and will allow ...
(Date:1/18/2017)... ... 18, 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), ... for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. ... through thought leader interaction in, live video and interactive digital platforms. , In ...
(Date:1/18/2017)... Hills, CA (PRWEB) , ... January 18, 2017 ... ... of dental problems ranging from gum disease to enamel erosion, and those dental ... the Massachusetts Department of Public Health, many pregnant women are failing to get ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Anesthesia Progress ... for dentists to choose the best drug option for each patient. Dentists have several ... and better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
(Date:1/18/2017)... , Jan. 18, 2017  EnteroMedics Inc. (NASDAQ: ... devices using neuroblocking technology to treat obesity, metabolic ... pricing of an underwritten public offering of units ... deducting underwriting discounts and commissions and offering expenses ... comprised of Class A Units, priced at a ...
(Date:1/18/2017)... Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the ... partnership with Hyatt Place Nashville/Downtown to deliver the best ... sleep therapy machines in over two hundred of its ... important parts of having a great stay is sleeping ... Hyatt Place Nashville/Downtown. "We,re pleased to be able to ...
Breaking Medicine Technology: